CA Patent

CA2479638A1 — Hfa-suspension formulations of crystalline tiotropium bromide anhydrate

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2003-10-09 · 23y expired

What this patent protects

The invention relates to propellant formulations containing suspensions of a crystalline anhydrate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7- [(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatricyclo[3.3.1.02,4]nonane bromide.

USPTO Abstract

The invention relates to propellant formulations containing suspensions of a crystalline anhydrate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7- [(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatricyclo[3.3.1.02,4]nonane bromide.

Drugs covered by this patent

Patent Metadata

Patent number: CA2479638A1
Jurisdiction: CA
Classification: —
Expires: 2003-10-09
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim Pharma GmbH and Co KG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.